<DOC>
	<DOCNO>NCT01949168</DOCNO>
	<brief_summary>The purpose study evaluate antiviral efficacy Boceprevir-based therapy treatment genotype 6 chronic hepatitis C infection . Boceprevir recently approve treatment genotype 1 chronic hepatitis C infection . Recent vitro study suggest similar efficacy genotype 6 chronic hepatitis C infection . The investigator therefore hypothesise : ) Boceprevir potent inhibitor genotype 6 hepatitis C replication vivo . ii ) Boceprevir combination pegylated interferon-alpha ribavirin 24 week cure high proportion patient chronically infect genotype 6 chronic hepatitis C infection .</brief_summary>
	<brief_title>A Pilot Study Boceprevir Treatment Genotype 6 HCV</brief_title>
	<detailed_description>Genotype 6 HCV ( HCV-6 ) common part South-East Asia , particular Vietnam . There small grow population immigrant patient chronic HCV-6 Australia . The current standard-of-care treatment ( SOC ) chronic HCV-6 infection peg-interferon-α ( PEG-IFN ) ribavirin ( RBV ) therapy 48 week . The available data evaluate treatment outcome suggest SVR rate intermediate HCV-1 HCV-2/3 . There medical need novel therapy might increase SVR rate and/or allow shorten treatment duration . Boceprevir novel HCV NS3 protease inhibitor , boceprevir-based triple therapy recently approve treatment HCV-1 . Boceprevir also appear antiviral effect HCV-2 HCV-3 vivo . Boceprevir use treat patient chronic HCV-6 infection . Recent vitro data demonstrate boceprevir antiviral effect HCV-6 . The investigator therefore undertake investigator-initiated proof-of-concept pilot study boceprevir-based therapy treatment patient chronically infected HCV-6 . The study population consist representative group 30 adult patient chronically infect genotype 6 HCV . All patient Asian background , non-cirrhotic , carry `` good response '' IL28B genotype ( C/C rs12979860 ) . The patient recruit outpatient clinic 4 Hepatology unit Melbourne , Australia , represent principal associate investigator .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Male female , least 18 year age Asian background HCV treatmentnaïve . Chronic HCV infection define one following : Positive antiHCV antibody ( Ab ) HCV RNA least 6 month Screening , positive HCV RNA antiHCVAb time Screening ; Positive antiHCV Ab HCV RNA time Screening liver biopsy consistent chronic HCV infection ( liver biopsy perform prior enrollment evidence chronic hepatitis C disease ) . Screening laboratory result indicate HCV genotype 6infection ( HCV6 ) . Plasma HCV RNA level &gt; 10,000 IU/mL Screening . IL28B C/C genotype ( rs12979860 ) Per local standard practice , document result one following : A liver biopsy within 24 month prior screen demonstrate absence cirrhosis , e.g. , METAVIR Score 3 less , Ishak score 4 le ; A screening FibroTest score ≤ 0.72 Aspartate Aminotransferase Platelet Ratio Index ( APRI ) ≤ 2 ; A screening FibroScan result &lt; 9.6 kPa . Subjects nonqualifying Fibrotest/APRI Fibroscan result may enrol qualify liver biopsy preform within 24 month prior screen . Candidate PEG/RBV therapy Body mass index ( BMI ) 18 36 kg/m2 Agree use two highly effective method avoid contraception duration study 7 month last dose study medication . Females childbearing potential must negative pregnancy test Screening Baseline Provide write informed consent participate study . Subjects must follow laboratory parameter Screening : ALT ≤ 10 × upper limit normal ( ULN ) AST ≤ 10 × ULN Hemoglobin ≥ 12 g/dL White blood cell count ≥ 2,500 cells/μL Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm3 Platelets ≥ 90,000/mm3 Prothrombin time ≤ 1.5 × ULN Albumin &gt; 3 g/dL Direct ( conjugate ) bilirubin &lt; ULN Thyroid stimulate hormone ( TSH ) ≤ ULN Creatinine clearance ( CLcr ) ≥ 50 mL/min , calculate CockcroftGault equation Nongenotype 6 HCV infection , evidence mixed genotype HCV infection IL28B C/T T/T polymorphism ( rs12979860 ) Any current past clinical evidence cirrhosis ascites esophageal varix , prior biopsy show cirrhosis , e.g. , Metavir Score &gt; 3 Ishak score &gt; 4 . Exceed define threshold key laboratory parameter Screening . Females pregnant plan become pregnant , breastfeeding , male whose partner pregnant plan become pregnant within 7 month ( per local RBV label ) last dose study drug . Positive test result Hepatitis B surface antigen ( HBsAg ) antiHuman immunodeficiency virus antibody ( HIV Ab ) . Diagnosis autoimmune disease , decompensated liver , disease , poorly control diabetes mellitus , significant psychiatric illness , severe chronic obstructive pulmonary disease ( COPD ) , hepatocellular carcinoma malignancy ( exception certain skin cancer ) , hemoglobinopathy , retinal disease , immunosuppressed Subjects current use amphetamine , cocaine , opiate ( e.g. , morphine , heroin ) , ongoing alcohol abuse exclude . Subjects stable methadone maintenance treatment least 6 month prior Screening may include study . Use prohibit concomitant medication two week prior baseline end treatment , define product label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>